13063_2018_2613_MOESM1_ESM.doc (122.5 kB)
Additional file 1: of Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial
journal contribution
posted on 2018-04-12, 05:00 authored by Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-VuilleminSPIRIT checklist. (DOC 122Â kb)